leadf
logo-loader
viewQ BioMed Inc.

Q BioMed to begin production of its potential coronavirus therapeutic with partner Mannin Research

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the group will begin production MAN-19, a clinical grade therapeutic intended to treat complications caused by the coronavirus.

Corin says the Phase 1 clinical trial, which will be conducted with technology partner Mannin Research, is slated to begin patient enrollment in February 2021.

Quick facts: Q BioMed Inc.

Price: 1.05 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $24.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Q BioMed makes Strontium89 available to US urology doctors with purchasing...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive it has been awarded a contract with UroGPO, the largest group purchasing organization for urology private practice clinics in the US, to make its bone pain treatment Strontium89 available to doctors. Corin says through the partnership,...

3 weeks, 3 days ago

2 min read